MX2023005375A - Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. - Google Patents

Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.

Info

Publication number
MX2023005375A
MX2023005375A MX2023005375A MX2023005375A MX2023005375A MX 2023005375 A MX2023005375 A MX 2023005375A MX 2023005375 A MX2023005375 A MX 2023005375A MX 2023005375 A MX2023005375 A MX 2023005375A MX 2023005375 A MX2023005375 A MX 2023005375A
Authority
MX
Mexico
Prior art keywords
claudin6
treatment
expressing cancer
antibodies binding
cancer diseases
Prior art date
Application number
MX2023005375A
Other languages
English (en)
Inventor
Maria Kreuzberg
Gall Fabrice Le
Christiane Stadler
Arne Jendretzki
Özlem Türeci
Ugur Sahin
Leyla Fischer
Original Assignee
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag filed Critical Biontech Ag
Publication of MX2023005375A publication Critical patent/MX2023005375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona agentes de unión que comprenden al menos tres dominios de unión, en donde un primer dominio de unión se une a un antígeno específico de células T y un segundo dominio de unión y un tercer dominio de unión se une a una claudina, y los métodos de uso de estos agentes de unión o ácidos nucleicos que se codifican para el tratamiento del cáncer.
MX2023005375A 2016-09-23 2019-03-22 Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. MX2023005375A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/072688 WO2018054484A1 (en) 2016-09-23 2016-09-23 Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Publications (1)

Publication Number Publication Date
MX2023005375A true MX2023005375A (es) 2023-05-22

Family

ID=57003498

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003350A MX2019003350A (es) 2016-09-23 2017-09-20 .anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MX2023005375A MX2023005375A (es) 2016-09-23 2019-03-22 Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019003350A MX2019003350A (es) 2016-09-23 2017-09-20 .anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.

Country Status (14)

Country Link
US (2) US11787862B2 (es)
EP (2) EP3515939A1 (es)
JP (3) JP7055794B2 (es)
KR (2) KR102537091B1 (es)
CN (2) CN118388656A (es)
AU (2) AU2017331331B2 (es)
BR (1) BR112019002168A2 (es)
CA (1) CA3034186A1 (es)
IL (3) IL264233B (es)
MX (2) MX2019003350A (es)
NZ (1) NZ750132A (es)
SG (1) SG11201901899PA (es)
WO (2) WO2018054484A1 (es)
ZA (2) ZA201900962B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
JP7513605B2 (ja) * 2018-07-18 2024-07-09 アスクジーン・ファーマ・インコーポレイテッド 新規な抗体ならびにそれを調製および使用するための方法
UY38326A (es) * 2018-08-03 2020-01-31 Amgen Inc Constructos de anticuerpos para cldn18.2 y cd3
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
EP3904386A4 (en) * 2018-12-28 2022-09-07 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTIBODIES AND USE THEREOF
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020156554A1 (zh) * 2019-02-01 2020-08-06 科济生物医药（上海）有限公司 Tcr融合蛋白及表达tcr融合蛋白的细胞
CN113767113A (zh) 2019-02-15 2021-12-07 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
EP3947468A1 (en) * 2019-03-29 2022-02-09 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
CN117264059A (zh) * 2019-05-16 2023-12-22 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
CN113950485A (zh) * 2019-07-10 2022-01-18 中外制药株式会社 密蛋白-6结合分子及其用途
WO2021011885A1 (en) 2019-07-17 2021-01-21 The Regents Of The University Of California Claudin18 antibodies and methods of treating cancer
SG11202104264TA (en) * 2020-03-31 2021-11-29 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
WO2021237717A1 (zh) * 2020-05-29 2021-12-02 武汉友芝友生物制药有限公司 抗cldn18.2和cd3的双特异性抗体
JP2023531672A (ja) * 2020-06-30 2023-07-25 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
WO2022100613A1 (zh) * 2020-11-10 2022-05-19 上海齐鲁制药研究中心有限公司 针对密蛋白18a2和cd3的双特异性抗体及其应用
AU2022232375A1 (en) * 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
EP4349870A1 (en) * 2021-06-02 2024-04-10 Qure Biotechnology (Shanghai) Co., Ltd. Anti-cd3 antibody variant, fusion protein, and application
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
US20240247062A1 (en) * 2021-06-15 2024-07-25 Xencor, Inc. Heterodimeric antibodies that bind claudin18.2 and cd3
MX2024000678A (es) * 2021-07-15 2024-02-07 BioNTech SE Agentes que codifican elementos de union a cldn6 y cd3 para el tratamiento de canceres positivos para cldn6.
US20240344030A1 (en) * 2021-07-28 2024-10-17 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody
WO2023185732A1 (zh) * 2022-03-28 2023-10-05 信达生物制药（新加坡）有限公司 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024126457A1 (en) * 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024184810A1 (en) * 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
CN116087069B (zh) * 2023-04-10 2023-08-08 苏州药明康德新药开发有限公司 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PL218660B1 (pl) 2002-10-17 2015-01-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
CN1326881C (zh) * 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US10093736B2 (en) * 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
JP6721590B2 (ja) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN107406509B (zh) * 2014-12-19 2021-10-29 凯奥目生物科学株式会社 包含结合至5t4和cd3的三个结合结构域的融合蛋白
WO2016135239A1 (en) * 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2

Also Published As

Publication number Publication date
JP2019535234A (ja) 2019-12-12
RU2019112165A (ru) 2020-10-23
IL264233B (en) 2022-03-01
ZA202002471B (en) 2021-09-29
BR112019002168A2 (pt) 2019-09-17
CN110023336B (zh) 2024-05-17
US20190309067A1 (en) 2019-10-10
CN118388656A (zh) 2024-07-26
JP2024054250A (ja) 2024-04-16
WO2018054484A1 (en) 2018-03-29
ZA201900962B (en) 2020-10-28
KR20190052002A (ko) 2019-05-15
KR102537091B1 (ko) 2023-05-31
AU2017331331A1 (en) 2019-02-07
CA3034186A1 (en) 2018-03-29
IL290234A (en) 2022-03-01
IL264233A (en) 2019-02-28
EP4043494A1 (en) 2022-08-17
WO2018054973A1 (en) 2018-03-29
US20240158501A1 (en) 2024-05-16
IL290230A (en) 2022-03-01
MX2019003350A (es) 2019-08-12
CN110023336A (zh) 2019-07-16
KR20230074637A (ko) 2023-05-30
JP7436552B2 (ja) 2024-02-21
AU2022200283A1 (en) 2022-02-17
SG11201901899PA (en) 2019-04-29
US11787862B2 (en) 2023-10-17
JP2022091973A (ja) 2022-06-21
JP7055794B2 (ja) 2022-04-18
RU2019112165A3 (es) 2021-01-20
AU2017331331B2 (en) 2022-03-10
EP3515939A1 (en) 2019-07-31
AU2022200283A2 (en) 2022-04-21
NZ750132A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
NZ769968A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
NZ707831A (en) Agents for treatment of claudin expressing cancer diseases
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
PH12016501384B1 (en) Human antibodies to pd-l1
MY179866A (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EP3766903A3 (en) Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA202090303A3 (ru) Композиции антител для лечения опухолей